Feigelson H S, Coetzee G A, Kolonel L N, Ross R K, Henderson B E
Department of Preventive Medicine, University of Southern California School of Medicine, Los Angeles 90033-0800, USA.
Cancer Res. 1997 Mar 15;57(6):1063-5.
We conducted a case-control study to determine whether a polymorphism in the CYP17 gene was associated with risk of breast cancer. We found an increased risk of advanced breast cancer in women carrying an A2 allele. The odds ratio was 2.5 [95% confidence interval (CI), 1.07-5.94] for regional or metastatic disease. Among controls, the A1/A1 genotype was associated with a later age at menarche. The reduced risk of breast cancer associated with a later age of menarche was largely limited to A1/A1 women: odds ratio, 0.47 (CI, 0.22-0.98) for breast cancer and later age at menarche among A1 homozygotes compared with 0.80 (CI, 0.51-1.27) for A1/A2 and A2/A2 genotypes. These findings suggest that the CYP17 genotype may be a biomarker for the onset of ovulation and advanced breast cancer risk.
我们开展了一项病例对照研究，以确定CYP17基因多态性是否与乳腺癌风险相关。我们发现携带A2等位基因的女性患晚期乳腺癌的风险增加。对于局部或转移性疾病，比值比为2.5[95%置信区间(CI)，1.07 - 5.94]。在对照组中，A1/A1基因型与初潮年龄较晚相关。初潮年龄较晚与乳腺癌风险降低之间的关联在很大程度上仅限于A1/A1女性：A1纯合子中，初潮年龄较晚与乳腺癌的比值比为0.47(CI，0.22 - 0.98)，而A1/A2和A2/A2基因型的比值比为0.80(CI，0.51 - 1.27)。这些发现表明，CYP17基因型可能是排卵开始和晚期乳腺癌风险的生物标志物。
